You are currently viewing a new version of our website. To view the old version click .
Polymers
  • Review
  • Open Access

11 February 2025

The Potential of Hydrogel Preparations Containing Plant Materials in Supporting the Treatment of Vaginal and Vulvar Infections—Current State of Knowledge

,
,
and
1
Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia,41-200 Sosnowiec, Poland
2
Department of Pharmaceutical Sciences, Medical College, Jan Kochanowski University, 25-317 Kielce, Poland
3
Clinical Department of Perinatology and Oncological Gynaecology, Medical University of Silesia, 41-200 Sosnowiec, Poland
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Innovations in Hydrogel Design for Pharmaceutical and Medical Applications

Abstract

Vaginal hydrogels are a modern alternative to solid (tablets, globules) and other semi-solid forms of medication (ointments, creams) in the control of pathogenic microorganisms in diseases of the female reproductive tract. This review aims to summarize the current state of knowledge regarding the efficacy of hydrogels containing plant materials in the treatment of vaginal and vulvar infections. New therapies are essential to address the growing antimicrobial resistance crisis. Google Scholar, Web of Science, Cochrane, and Medline (PubMed) databases were searched. Twenty-five studies were included in the review, including basic, pre-clinical, and clinical studies. The results obtained confirmed the therapeutic potential of plant raw materials embedded in the polymer matrix of hydrogels. However, due to the small number of clinical trials conducted, further research in this area is needed.

1. Introduction

Antimicrobial drug resistance is one of the biggest problems in modern medicine. Limited research into new antibiotics/therapies and the overuse of currently available ones on the market have made antibiotic resistance a serious health threat. The World Health Organization (WHO) has identified it as one of the top 10 global public health threats. The European Centre for Disease Prevention and Control (ECDC) estimates 33,000 deaths annually (EU and EEA area) due to antimicrobial resistance. It is projected that this number could rise to 10 million per year by 2050 [1]. The search for compounds with proven therapeutic activity in the face of increasing chemotherapeutic resistance in the treatment of bacterial and fungal infections of the vagina and vulva is therefore imperative. Research is currently being conducted in several directions. One strategy involves the development of combination therapies, using the synergistic action of two or more compounds. Other research is focused on finding new compounds dedicated to the pharmacotherapy of a specific infection. An increasing amount of research is directed toward finding natural therapies using plant materials. It should be borne in mind, however, that treatment based on phytotherapy is for the long term and is mainly considered an adjunctive treatment.

2. Materials and Methods

2.1. Focused Questions

Do hydrogel preparations containing plant materials show therapeutic potential in the treatment of vaginal and vulvar infections?

2.2. Eligibility Criteria

The article provides a narrative review of the literature. Google Scholar, Web of Science, Cochrane, and Medline (PubMed) databases were searched using a combination of MeSH terms, including “hydrogel”, “polymer”, “semi-solid formulation”, “herbal”, “natural compounds”, “Candida”, “Streptococcus”, “vulvovaginal candidiasis”, “therapeutic treatment”, “vaginal infection”, “antibiofilm activity”, “antifungal”, “bacterial vaginosis”, and “physiochemical properties”. The search procedure has been simplified by using the “AND” operator. Articles published in peer-reviewed journals that included the above-mentioned keywords in their titles and/or abstracts were included. Studies published up to December 2024 were included, with a focus on publications from the last 30 years. Inclusion criteria were original papers with data from basic, preclinical, and clinical studies. Hydrogels based on different types of polymers containing raw materials of plant origin were included. Exclusion criteria were articles that investigated another semi-solid form of drug for vaginal administration containing a plant-based raw material (creams, ointments). Letters to the editor and studies published on websites and in newsletters were not included in the review.

3. Causes and Symptoms of Vaginal and Vulvar Infections

One of the most common reasons for patients presenting to gynecologists is a set of symptoms that may indicate vulvovaginitis [2]. These include itching, burning, pain in the urogenital area (also during intercourse), unpleasant vaginal odor, and painful urination [2,3].
A history unsupported by other clinical data suggesting an inflammatory etiology is often insufficient to make a correct diagnosis. Correct management also involves a physical examination and microbiological tests to confirm the initial diagnosis [4]. Finding the cause of the patient’s symptoms is extremely important, as similar symptoms may occur in non-infectious diseases such as lichen sclerosus, lichen planus, psoriasis, vulvodynia, cancer, or allergies to the detergents used for intimate area care [3]. Incorrect diagnosis delays the elimination of bothersome complaints, reducing quality of life and exposing the patient to unnecessary prolonged pharmacotherapy [4].
The microflora of the reproductive tract of women of childbearing age includes many aerobic and anaerobic bacterial species. Although it is accepted that the main strain colonizing the female reproductive tract is Lactobacillus spp., it is worth mentioning the somewhat less obvious species, which include Streptococci type B (GBS), Staphylococcus aureus, Escherichia coli, Klebsiella spp., and others [3].
The composition of the microflora before puberty in girls and during menopause in women is poorer in lactic acid bacilli, among others, largely resembling the skin microflora. This is related to significantly lower concentrations of estrogen and glycogen, two key factors required for the colonization of the reproductive tract by Lactobacillus spp. All components are reflected in the fact that in groups of young girls and older women, the pH of the reproductive tract is closer to neutral (6.0–7.5) in contrast to women of reproductive age (vaginal pH in the range of 3.8–4.2 due to the presence of lactic acid produced by Lactobacillus spp.) [3]. For the reasons mentioned above, vulvovaginal infections in these age groups may have a different course. One of the pitfalls concerning the menopausal period may be the symptoms of atrophic vaginitis (part of the urogenital syndrome), which may mistakenly resemble the development of an infection [3].
The development of vulvovaginitis most often has its origin in an imbalance of vaginal biocenosis in favor of a proliferation of pathogenic microorganisms. Such a condition is defined as dysbiosis [3]. It is estimated that every woman will experience an episode of vulvovaginitis at least once in her lifetime [2]. The most common etiology includes bacterial infection (depending on sources, 20–60%; average: 40–50% of cases) [3,5], yeast infection (20–25%) [3], cysticercosis, and viral infection (e.g., HSV—Herpes Simplex Virus) [2,3].
Wearing cotton underwear, correct intimate hygiene techniques, the use of condoms (especially during incidental sexual contact), avoiding vaginal irrigation, and regular testing for sexually transmitted diseases play a very important role in the prevention of infection [3,5].
A bacterial vaginal infection called bacterial vaginosis (BV) is a condition in which there is an excessive proliferation of pathological bacterial flora as species such as Gardnerella vaginalis, Mycoplasma hominis, Mobiluncus spp., and others [3]. The overriding symptom is an unpleasant fishy odor emanating from the genital tract along with an increased amount of gray or white-colored discharge. However, the typical inflammation manifested by erythema, fissures, and bleeding of the irritated mucosa is absent. Some patients may not present with any symptoms. The main risk factors for bacterial vaginitis include vaginal irrigation, excessive hygiene of the intimate area, smoking, frequent change in sexual partners, and homosexual contact between women. It is noteworthy that bacterial vaginosis may favor the development of other infections in the genital tract, influencing a local reduction in the immune response and the release of endotoxins that facilitate the initiation of inflammation in the presence of another pathogenic agent [3,5].
A vulvovaginal infection caused by a fungus of the Candida species (most commonly Candida albicans) is called vaginal candidiasis. It accounts for approximately one-third of all vulvovaginal infections; 70% of patients have experienced at least one episode of candidiasis in their lifetime, while 8% struggle with recurrent infections. Classic symptoms include pruritus, burning, and discharge of thick white vaginal discharge [2,3,6]. At this time, there is a lack of evidence to suggest that a high number of sexual partners may contribute to the development of vulvar candidiasis [6]. However, it is known that pregnancy, diabetes mellitus, obesity, recent antibiotic therapy, and immunocompromised states (long-term intake of corticosteroids and antimetabolites, organ transplant status, HIV infection) predispose to its onset [2,3,6].
Trichomonas vaginalis is one of the more common causes of vulvovaginitis, according to sources accounting for 3.2–8.9% of infections [7]. Patients with trichomoniasis report typical symptoms of vulvovaginal infection, including pruritus, discharge with a runny and foamy consistency, yellow or green color, and a specific odor [2,7]. On speculum gynecological examination, T. vaginalis infection can be suspected based on a cervix with an appearance resembling the structure of a strawberry [6].
Treatment of the above-described infections follows a variety of regimens. The main antibiotics used to treat BV and cervicitis are metronidazole and tinidazole orally and vaginally [5,7], while candidiasis is treated with drugs from the azole group, also orally or vaginally [2,6]. Due to frequent co-infection with multiple microorganisms, combination preparations of nystatin and nifuratel by the vaginal route are acceptable [8]. Approximately 30% of BV cases are spontaneously curable without pharmacotherapy. An asymptomatic course of BV infection does not require any treatment [5].

4. Importance of Plant Raw Materials Used in the Treatment of Gynecological Diseases

Resistance to commonly used pharmacological treatments has prompted increased interest in plant-based alternatives in gynecological practice. Plant extracts are increasingly becoming an object of interest in combating pathogenic microorganisms in diseases of the female reproductive tract. Plants are abundant in biologically active compounds (e.g., flavonoids, phenolic acids, tannins, mucilages, azulenes) or components of essential oils (e.g., thymol, carvacrol, myrcene, α-terpineol, 1,8-cineole, eugenol, α-terpinene, linalool, geraniol, menthone, β-pinene, borneol, sabinene, limonene, p-cymene, thymol, menthol) found in various parts of the plant, including leaves, flowers, aerial parts, fruits, roots, seeds, or shoulders (Table 1). The multidirectional action of plant raw materials allows for their use in the treatment of many gynecological diseases, either as an alternative or natural support in the treatment process [9,10,11].
Table 1. The most important bioactive compounds and their effects, as well as examples of plant raw materials used in the treatment of gynecological diseases and in the care of intimate areas [9,12,13].
The available literature indicates the potential use of plant materials for amenorrhea (e.g., Aloe barbadensis Mill., Carica papaya L., Tamarindus indica L., Sambucus nigra L., Petroselinum crispum (Mill.) Fuss, Pimpinella anisum L.), dysmenorrhea (Acacia leucophloea L., Eclipta prostrata L., Tephrosia purpurea Pers., Valeriana officinalis L., Salvia rosmarinus Spenn.), leucorrhea (Asparagus racemosus Wild., Nelumbo nucifera Gaertn., Smilax zeylanica L., Clitoria ternatea L.), menorrhagia (Cassia occidentalis L., Mangifera indica L., Desmodium triflorum L.), gonorrhea (e.g., Lawsonia inermis L., Ficus religiosa L., Ceiba pentandra L.), premenstrual syndromes (PMSs) (e.g., Vitex agnus-castus L., Lycopus europeaus L., Cimicifuga racemosa L., Crocus sativus L., Gingko biloba L., Hypericum perforatum L.), or human papilloma virus (HPV) infection (e.g., Podophyllum peltatum L., Thuja occidentalis L.) [10,12,14,15,16]. Several plants are also known to be recognized in traditional medicine as having protective and therapeutic properties, including in the context of anti-inflammatory protection (e.g., Calendula officinalis L., Achillea millefolium L., Chamomilla recutita L.) and antimicrobial properties (e.g., Trigonella foenum-graecum L., Azadirachta indica A. Juss., Cichorium intybus L., Thymus vulgaris L., Paeonia suffruticosa Andr.) [9,12,13,17].
In the treatment of gynecological diseases, raw materials of plant origin can be dosed orally (e.g., decoction, infusion, capsules) or vaginally (e.g., vaginal suppositories, pills, solutions, ointments, creams, gels) [10].

5. Potential of Hydrogels in Vaginal Administration

The concept of developing vaginal preparation in the form of a hydrogel stems from the search for alternative forms to the solid and semi-solid drug forms often used. The versatility of tablets, capsules, and vaginal globules is due to their ease of production and greater stability of the drug form. The disadvantage of their use is the risk of uncontrolled removal if applied too shallowly. In addition, vaginal tablets and capsules are pH-dependent, so that API (active pharmaceutical ingredient) absorption can be variable and incomplete in the treatment of various conditions when the pH exceeds 4.5. The physiological conditions of vaginal administration are also a problem. An amount of vaginal secretions of approximately 2 mL may limit the solubility of the active substance [18]. On the other hand, lipophilic ointments and o/w creams do not ensure adhesion to the mucosa and mix poorly with vaginal secretions [19]. An additional advantage of hydrogels is their ease of preparation and low production cost. Current research is being conducted for the development of novel hydrogel drug carriers for gynecological applications.
Hydrogels are matrices containing a loosely cross-linked polymeric structure filled with water. Weak physical hydrogels, in which the polymer chains are mainly linked by hydrogen bonds, are most commonly used for vaginal administration [20]. Common polymers used are Carbopol, polyvinyl alcohol, poloxamer (Pluronic), cellulose derivatives (hydroxypropyl methylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethylcellulose), polyethylene glycol, xanthan gum, chitosan, sodium alginate, hyaluronic acid, and others [21,22,23]. It is required that the formulated preparation has the ability of mucoadhesion to the vaginal mucosa, which increases its contact time with the vaginal surface and the bioavailability of the therapeutic substance. The gynecological hydrogel should be easy to apply and non-allergenic and non-irritating to the mucosa. It is important that it has the appropriate rheological and texture properties to allow for optimal spreading of the preparation in the vagina [24]. The challenge is to develop the technology to incorporate the therapeutic substance into the hydrogel matrix, ensuring its prolonged release profile. The introduction of the API as a solution/suspension into the system affects the cross-linking process and the properties of the resulting hydrogel material. Too large a volume of the drug formulation may interfere with the preparation of the hydrogel preparation, while too small a volume may affect its therapeutic properties. A problem that must also be taken into account is the varying vaginal environment during a woman’s life (volume, composition, and pH of vaginal fluids). The pH changes with age, with the phase of the menstrual cycle, with estrogen levels, and with changes in the composition of cervical mucus [25]. Maintaining adequate vaginal pH is one of the most important factors for the effective action of drugs.
The development of pH- or temperature-sensitive gel matrices is one of the current research directions. Under the influence of these factors, the liquid form, i.e., a sol, is transformed into a semi-solid hydrogel form at the application site. The most commonly used so-called smart polymers for the preparation of gels are Carbopol, poloxamer 407, chitosan, alginate, and others. To prolong the API release time from an in situ gynecological gel, the formulation is often supplemented with an additional polymer to increase the viscosity of the system [26]. Other work focuses on the technology to prepare a hydrogel matrix that undergoes mucoadhesion over several days and increases its viscosity when interacting with the vaginal mucosa [27,28]. Attempts are also being made to incorporate multi-compartmental forms of the drug into the hydrogel formulation. The most popular modification is hydrogel matrices containing liposomes [29]. Gels with microspheres or gelled emulsions are also being developed [30].

6. Review of Studies on Vaginal Hydrogel Preparations Containing Plant Materials

Table 2 describes the raw materials of plant origin present in the formulation of the hydrogel preparations for vaginal administration discussed in this paper.
Table 2. Characterization of the plant raw materials contained in the hydrogel preparations in question for vaginal administration.
By analyzing Table 2, it can be concluded that many chemical compounds have been isolated from plant raw materials, which translates into their diverse mechanisms of action (e.g., antiseptic, anti-bacterial, antifungal, anti-inflammatory, antioxidant, antiviral effects) and, consequently, the possibility of therapeutic activity.
The content of a polymer matrix can be examined by several methods, most commonly by the incorporation of lyophilized hydrogels into an API solution, homogeneous mixing of bioactive compounds with the polymer in the base precursor, and by covalent binding of active compounds to macromers before the gelation process. Incorporating bioactive compounds into the hydrogel has been found to stabilize bioactive interactions [70]. The chemical affinity of bioactive compounds to the polymer/polymers of the hydrogel matrix (having a large number of domains or hydrophilic groups) is dependent on the water solubility of the plant materials and intermolecular interactions with the functional groups of the polymer hydrogels, i.e., hydrogen bonding interactions with functional groups of the polymer chain such as -OH, -NH2, solvophobic effects, and π-π-type interactions between phenolic rings in the plant material [71]. The release of the therapeutic substance from the hydrogel can occur in a controlled manner by diffusion, swelling, or chemical reactions directly into the area requiring treatment. An important determinant of the controlled release of the API is the hydrogel’s degradation rate. Polymeric matrices characterized by a less compact structure and higher water content degrade more rapidly compared to hydrogels with a higher cross-linking density due to the increased mobility of the polymer chains [72]. Figure 1 shows the distribution and diffusion of bioactive substances from the hydrogel after vaginal application.
Figure 1. Distribution and diffusion of bioactive substances from the hydrogel after vaginal application.
Table 3 summarizes the current state of knowledge on the efficacy of hydrogels containing plant ingredients in the treatment of vaginal infections.
Table 3. Research on the therapeutic efficacy of hydrogels containing plant materials.
The therapeutic potential of hydrogels containing raw materials of plant origin is discussed, taking into account the regions of the world where the plant is found.

6.1. Basic and Pre-Clinical Research

6.1.1. Global Coverage

Trigonella foenum-graecum is native to Asia and Eastern Europe. It is now widely cultivated worldwide [98]. Cichorium intybus is cultivated in Europe, India, South Africa, and Chile [99]. Curcuma longa is found in India, China, Malaysia, northern Australia, Thailand, and Indonesia [100]. Azadirachta indica is a plant native to India [101]. Chopra et al. [74] analyzed polyherbal gels based on Trigonella foenum-graecum, Azadirachta indica, Cichorium intybus, and Curcuma longa (NAC) for vaginal drug delivery. A novel vaginal drug delivery system for the topical treatment of aerobic vaginitis was evaluated for its rheological and mucoadhesive properties. Three types of structurally similar and cross-linked acrylic acid polymers. namely Carbopol 934P, Carbopol 974P, and Noveon AA-1 (polycarbophil), in combination with honey and aerosol (fumed silica), were used in this study. The NAC content was 250 mg. A three-level Box–Behnken plan was used to optimize the gel formulation for the highest gel strength and mucoadhesion. The analyzed formulations showed characteristics of viscoelastic solids (G′ > G″). In the in vitro release study, NAC was found to be released from the formulation rapidly within the first hour (according to the zero-order model), while it was released in a prolonged manner over the following 23 h (according to the Korsmeyer-Peppas model). Stability analysis was performed according to ICH guidelines, and the formulations were found to be stable at 6 months. No degradation of NAC and no changes in release profiles were observed in vitro (ANOVA, p > 0.05).
Black cumin is native to a vast region of the eastern Mediterranean, northern Africa, the Indian subcontinent, and Southwest Asia, while the olive tree is traditionally found in the Mediterranean basin [102,103]. Sangi et al. [76] attempted to develop a mucoadhesive vaginal gel with microspheres containing Nigella sativa and Olea europaea oil. Microspheres prepared by the spray drying method were mixed with the carrier using an electric stirrer (50 rpm, 10 min) with a concentration of microspheres in 10% gel. This paper puts an emphasis on the surface morphology of the microspheres, as well as storage stability, in vitro release studies, and the rheological evaluation of gels based on 1% Carbopol 974P NF. The study revealed that the surface morphology of microspheres with black cumin and olive oil observed by a scanning electron microscope were shriveled. The preliminary rheological measurements showed that Carbopol 974P NF is a good matrix for preparing gels for vaginal use due to its good bioadhesive properties. The in vitro release study indicated that the N. sativa and O. europaea oil microspheres gel had a well-controlled release efficacy.
Thymbra capitata, a perennial and ornamental shrub, is an endemic plant to the Mediterranean region [104]. Palmeira-de-Oliveira et al.’s [77] study proposes a novel approach for the treatment of vulvovaginal candidiasis using TCCH hydrogel—T. capitata essential oil incorporated in low-molecular-weight chitosan solubilized in lactic acid. The volatile oil used in this study was obtained by hydrodistillation from the air-dried aerial parts of plants. The TCCH hydrogel was assessed for anti-Candida activity, including distinct Candida strains, such as C. albicans, C. glabrata, C. tropicalis, C. krusei, C. parapsilosis, and C. guilliermondii. It has been shown that the minimal concentration of the pharmaceutical formula containing Mediterranean thyme oil and chitosan with a pH consistent with the vaginal environment has a fungicidal effect on all tested Candida strains, both in neutral and acidic pH similar to the vaginal milieu. Confocal microscopy showed that the hydrogel interacts with the yeast cell surface without invasion of the cell. Furthermore, the final product was shown to have a strong effect on the biomass and metabolism of pre-formed Candida biofilms, and the antibiofilm effect of the TCCH hydrogel was dose dependent.
Thymus vulgaris is a perennial flowering plant found in Europe, Asia, the Mediterranean region, southeastern Italy, and northwestern Africa. About 90% of the world market for thyme oil is produced in Spain [105]. Vitis vinifera belongs to the Vitaceae family and is cultivated in Asia, North America, Europe, and regions in the subtropical, Mediterranean, and continental–moderate climate belts [106]. Opuntia ficus-indica belongs to the cactus family (genus Opuntia). The plant is native to Mexico and has become widespread in areas of Central and South America, Australia, the Mediterranean basin, and South Africa [107]. Moraru et al. [89] developed a hydrogel containing thyme essential oil and hydroglyceroalcoholic extracts of Vitis vinifera and Opuntia ficus-indica powder to help restore and/or maintain the natural vaginal microbiota and maintain its normal homeostasis. The authors investigated the structural and functional properties of two formulations of Kombucha BNC-PX and a hydrogel based on Kombucha BNC (bacterial nanocellulose), CS (chitosan), and PX (poloxamer 407) into which plant extracts/raw materials (thyme essential oil 0.5% v/v, hydroglyceroalcoholic extracts of Vitis vinifera 0.5% v/v, Opuntia ficus-indica powder 0.1% w/v) were incorporated. Fourier transform infrared spectroscopy (FTIR) and X-ray diffraction (XRD) studies verified daily PX in H1 and H2 in BNC-PX hydrogels, while H3 was in ternary CS packs. In the rheological component, the binary hydrogels push out thixotropy phenomena, while the ternary hydrogels fulfill rheopectic properties. The adhesion energies controlled by BNC-PX and BNC-PX-CS are 1.2 J/m2 and 9.1 J/m2, respectively. The formulations developed exhibited antimicrobial, antibiofilm, and a high degree of biocompatibility. The hydrogels promoted cell proliferation and promoted the growth of lactic acid bacilli. The test between the analyzed samples (assessed by a one-way ANOVA test) was found to be statistically significant at α = 0.05.
das Neves et al. [75] assessed the possible use of a polycarbophil-based gel containing thyme essential oil (carvacrol type) against Candida species, including C. albicans H37, C. albicans ATCC 10231, C. glabrata H16, and C. krusei H9. In addition to thyme oil (antifungal agent), polycarbophil (gelling agent and mucoadhesive), triacetin (fixative), lactic acid 90% (acidifier), hydrochloric acid (acidifier and solvent), propylene glycol (moisturizer and solvent), and triethanolamine (neutralizing agent) were used in the formulation of the gel. It has been shown that thyme essential oil possesses promising activity against species commonly involved in vulvovaginal candidiasis and gels with T. vulgaris volatile oil are a potent antifungal product. The MICs of both gels containing thyme essential oil as well as T. vulgaris essential oils determined at pH 5.5 or pH 7.0 were 0.32 mg/mL. Analyzing the results of the study, the authors concluded that the amount of oil used in the gel (1% w/w) was sufficient to achieve significant amounts of this substance in the vagina to be effective in the treatment of vaginal infections caused by Candida spp.

6.1.2. South America

Syngonanthus nitens is found only in South America [108]. dos Santos Ramos et al. [78] describe an interesting solution for the use of nanotechnology for drug delivery systems with mucoadhesive properties. The authors, based on previous knowledge regarding the antifungal properties of the species Syngonanthus nitens (Eriocaulaceae), evaluated the potential of a methanolic extract of scapes loaded in a precursor mucoadhesive liquid crystal system for the prevention of vaginal infections caused by Candida krusei (ATCC 6258). The formulation developed contained oleic acid as the oil phase, a polymeric dispersion containing synthetic polymers 2.5% Carbopol 974P and 2.5% polycarbophil as the aqueous phase, and PPG-5-CETETH-20 (polyoxypropylene (5) polyoxyethylene (20) cetyl alcohol) as the surfactant. The assessment of the prepared formulations by polarized light microscopy and rheology demonstrated isotropy. Nevertheless, the incorporation of 100% artificial vaginal mucus resulted in a more viscous and anisotropic solution. Moreover, the dilution of the liquid crystal compositions in the artificial vaginal mucus resulted in a notable enhancement in the mucoadhesion parameters. This allowed for a more robust interaction between the preparation and the vaginal mucosa, leading to prolonged retention within the vaginal environment. The antifungal assessments demonstrated that the golden grass extract exhibited activity against all strains examined, with an MIC range of 125 to 62.5 μg/mL. The incorporation of the plant extract into the formulation developed resulted in enhanced activity of S. nitens (decreased MIC). Furthermore, the time kill assays indicated that the tested extract was capable of controlling growth, suggesting a fungistatic mechanism. The results of the in vivo prophylactic test conducted on Wistar female rats demonstrated the efficacy of the extract loaded into the mucoadhesive liquid crystal hydrogel in preventing a vaginal infection caused by C. krusei, the etiological agent of vulvovaginal candidiasis. To summarize, the authors found that the incorporation of the golden grass extract into polycarbophil/Carbopol 974P-based liquid crystal hydrogel increased its antifungal activity. The formulation can be used as a prophylactic agent for vulvovaginal candidiasis.
The aim of further research of dos Santos Ramos et al. [79] was to broaden the knowledge about the methanolic extract of Syngonanthus nitens scapes loaded into a liquid crystal precursor system as a potential agent for the treatment of vulvovaginal candidiasis caused by Candida albicans. To prepare the liquid crystal precursor mucoadhesive system, oleic acid was used as the oil phase, while the water phase consisted of a 5% polymeric dispersion synthesized from two polymers, namely 0.5% polycarbophil and 0.5% Carbopol C974P. The surfactant in this system was polyoxypropylene (5) polyoxyethylene (20) cetyl alcohol (PPG-5-CETETH-20)—Procetyl. After incorporating the methanol plant extract into a formulation comprising 40% oil phase, 20% water phase, and 40% surfactant, the effective antifungal activity of the system for all strains tested (the standard strain of C. albicans (ATCC 10231)) and five clinical strains (CAV1, 2, 3, 4 and 5) with MICs ranging from 31.2 to 62.5 μg/mL was demonstrated. Microscopic observation revealed that the action of extract loaded into a system was superior to when the extract was not loaded. The analysis of the inhibitory profile of hyphae in C. albicans demonstrated an absence of filamentous cells within 24 h of exposure to a concentration of 31.2 μg/mL. The Syngonanthus nitens extract, which was not introduced into the drug delivery system, did not show effective activity against biofilms, while the extract incorporated into the liquid crystal precursor showed the inhibition of biofilms of all strains tested. In an in vivo study with Wistar female rats, a system with S. nitens extract was effective against C. albicans ATCC 10231 after 2 days of treatment and was more potent than the extract itself and the standard drug amphotericin B. Apart from antifungal effectiveness, the authors observed a significant increase in the mucoadhesive parameters, when the liquid crystal precursor compositions (the formulation with and without the plant extract) were diluted by the artificial vaginal mucus. The authors showed that an extract-loaded drug delivery nanotechnological system may be a promising tool in the treatment of vulvovaginal candidiasis. Moreover, it was confirmed that the incorporation into the drug delivery system is important for the increase in plant raw material pharmacological parameters.
Stryphnodendron adstringens is a native Brazilian plant [109]. Two research teams, Costa et al. [80] and de Freitas et al. [81], confirmed the efficacy of proanthocyanidin polymeric tannins extracted from Stryphnodendron adstringens in reducing the biofilm layer formed by fungi of the genus Candida spp. Costa et al. [80] prepared a hydrogel based on Carbopol 940 (1%), into which they incorporated a lyophilized aqueous fraction rich in proanthocyanidin polymers (0.2%). The authors confirmed the physical stability of the formulation. The MIC for C. albicans was 31.25 μg/mL. de Freitas et al. [81] used hydrogels containing tannin (fraction F2: 2.5 %w/w or 5% w/w) and a subfraction from the stem bark of Stryphnodendron adstringens (fraction F2.4) to treat mice with an induced vaginal infection with C. albicans, C. tropicalis, C. parapsilosis, C. glabrata. C. krusei, and C. guilliermondii. MICs were established for C. guilliermondii and C. glabrata (planktonic minimum inhibitory concentration/PMIC ≤ 0.48–3.91 μg/mL), as well as for C. albicans (PMIC ≤ 0.48–31.25 μg/mL). It was observed that formulations containing F2 and F2.4 showed similar efficacy against C. parapsilosis, C. krusei, and C. albicans. Efficacy against C. tropicalis was lower (p < 0.05). An in vivo study in BALB/c mice infected with C. glabrata and C. albicans, on the other hand, confirmed that the antifungal activity of gels containing F2 and F2.4 was greatest against C. glabrata strains than C. albicans (p < 0.05). The authors concluded that proanthocyanidins derived from Stryphnodendron adstringens extracts could be considered as a potential line of treatment for Candida infections caused by strains resistant to common antimycotics. The authors suggest that F2 and F2.4 are effective in the treatment of candidiasis in mice.
Copaifera officinalis grows in tropical regions of South America [110]. A potential therapeutic effect against Streptococcus agalactiae is shown by Copaifera officinalis, which is a source of oleoresin. Its mechanism of action mainly involves the disintegration of the bacterial cell wall and membrane. Morguette et al. [83]. prepared hydrogels based on Carbopol 940, into which they incorporated copaiba oil 0.5% (w/w) or 1.0% (w/w), obtaining, respectively, CARB-CO 0.5 and CARB-CO 1.0. In in vitro tests, copaiba oil was found to inhibit the growth of all GBS (group B Streptococcus) strains dose-dependently, including those resistant to erythromycin and clindamycin. MIC (minimal inhibitory concentration) values were 0.03 and 0.06 mg/mL, and MBC (minimal bactericidal concentration) values were 0.06 and 0.12 mg/mL (p > 0.05). Importantly, the oil did not inhibit the growth of Lactobacillus strains specific to the human microbiota. By contrast, when testing the developed hydrogels with incorporated copaiba oil in a Carbopol matrix, the authors confirmed antimicrobial activity against GBS strains only for CARB-CO 1.0. This formulation was biocompatible with mouse vaginal mucosa BALB/c. Furthermore, it was characterized by sustained release of the C. officinalis oleoresin and exhibited viscoelastic properties. The authors suggest that the Carbopol-based hydrogel is an effective carrier of copaiba oil and may be efficient in controlling S. agalactiae colonization and infection. The preparation does not affect the growth of Lactobacilli.
Mitracarpus frigidus is a shrub native to South America [111]. Campos et al. [85] developed a gynecological gel containing Mitracarpus frigidus (aerial parts) methanolic extract (MFM) and evaluated its efficacy in the treatment of vulvovaginal candidiasis (VVC) in a mouse model. The developed MFM–chitosan gel exhibited characteristics of a pseudoplastic fluid in rheological tests, with increasing viscosity and elasticity with increasing MFM extract concentration (2.5% w/w, 5.0% w/w, 10.0% w/w). SEM (scanning electron microscopy) studies confirmed the therapeutic effect of the developed formulation. A reduction in fungal infection was observed within six days of therapy. No inflammatory infiltration or erythrocytes were observed in the vaginal mucosa. The therapeutic efficacy of MFM–chitosan gel (10% w/w) was 89.43% and was comparable to the improvement after treatment with the reference formulation (Clotrimazole cream, 10 mg/g) (p < 0.05). The authors suggest that the hydrogel may be an alternative for the treatment of C. albicans VVC. In addition, the MFM–chitosan gel showed no harmful or toxic effects on the vulvovaginal system.
Commiphora leptophloeos is a species of plant found in Bolivia and southeastern Brazil [112]. Dantas-Medeiros et al. [87] evaluated the toxicity and therapeutic efficacy of a C. leptophloeos extract (4%) in the form of a vaginal hydrogel based on chitosan (1.0%) and poloxamer 407 (18%). They conducted the study in vitro and in G. mellonella, an alternative in vivo model. The formulation showed good physicochemical and microbiological stability and adequate rheological and textural parameters. The authors concluded that the developed hydrogel has high antifungal potential compared to C. leptophloeos extract alone at all concentrations used in vitro (2172–33.9 μg/mL) and in vivo at 125 mg/kg. The authors suggest that C. leptophloeos extract may be a promising pharmaceutical ingredient for the development of vaginal preparation.
Annona muricata (Annonaceae) is found in South America, mainly Brazil [113]. Campos et al. [91] investigated the antimicrobial efficacy of an ethanolic extract obtained from the leaves of A. muricata (AME) in an in vivo model of rat vulvovaginal candidiasis. The extract was incorporated into a Carbopol hydrogel matrix with AME concentrations of 1.0% (w/w), 2.5% (w/w), and 5.0% (w/w). A rheological study found that the incorporation of AME into the substrate decreased its viscosity and elasticity with increasing extract concentration, with all developed hydrogels being stable (G‘ > G’). An in vivo vaginal fungal load study confirmed that a Carbopol-based hydrogel with 2.5% AME reduced C. albicans infection by 79.9% after 6 days of treatment (2.13 log CFU/mL (day 1) vs. 0.45 log CFU/mL (day 6); p < 0.005). The control group consisted of rats treated with nystatin at a dose of 25,000 IU/g, which eliminated infection on the last, i.e., day 6 of treatment (2.05 log CFU/mL (day 1) vs. 0.00 log CFU/mL (day 6); p < 0.005). The authors suggest that the developed formulation may effectively support the treatment of vulvovaginal candidiasis.

6.1.3. Asia

Curcumin (CUR) is a compound extracted from the rhizomes of Curcuma longa, which is found in southern Asia [114]. Alves et al. [82] prepared thermoresponsive hydrogels based on poloxamer 407 (17–20 g) in combination with hydroxypropyl methylcellulose/HPMC K4M (0.3 g) and chitosan (0.3 g), adding them to curcumin (400 µg/mL, 600 µg/mL or 1200 µg/mL). The researchers used a technique called the solid dispersion technique. Easy-to-apply formulations with optimal cohesiveness, compressibility, adhesion, hardness, and mucoadhesion were obtained. Curcumin was released in a controlled manner according to the Hixson–Crowell model. The liquid-to-gel transition (Tsol-gel) occurred at 36 °C. The developed hydrogel could potentially improve the therapeutic activity of curcumin in vaginal administration. Carvalho et al. [92], based on previous studies, obtained a hybrid carrier nanoformulation (NIN) loaded with benzidamine hydrochloride/BNZ (with anti-inflammatory activity) and curcumin (with antifungal activity) using the microfluidics technique. The formulation was incorporated into a thermosensitive hydrogel based on poloxamer 407 and chitosan (HG). The resulting hydrogels were stable, with optimal rheological parameters. In a pharmaceutical availability study, 52.85% of curcumin was released from the CUR@NIN@HG formulation. The release occurred according to the Higuchi model, i.e., according to Fick’s diffusion kinetics. No antifungal activity of CUR was observed in vitro. However, its therapeutic effect was confirmed under in vivo conditions. Mice treated with CUR+BNZ@NIN@HG showed a reduction in spongiosis (p = 0.9815) on histopathology, which is associated with a decrease in fungal load. Hybrid nanoparticles loaded with curcumin and benzydamine hydrochloride minimize the toxicity of CUR and BNZ. The authors confirmed the antifungal and anti-inflammatory therapeutic potential of CUR+BNZ@NIN@HG and demonstrated its therapeutic equivalence to a commercial preparation (clotrimazole). During the experiment, the death of one rodent that was treated with free curcumin occurred (day 22 of the study).
Scutellariae baicalensis is found in Asia (eastern Russia, adjacent areas of Mongolia and China). The raw material for making extracts is the tap root [115]. Chanaj-Kaczmarek et al. [86] developed six binary formulations containing S. baicalensis radix extract, which they incorporated into a chitosan matrix. An amount of 1 g of lyophilized extract contained 178.10 ± 1.90 mg baicalin, 62.93 ± 1.23 mg baicalein, and 25.31 ± 0.19 mg wogonin. The 60% solutions of freeze-dried S. baicalensis radix extract were incorporated into a chitosan matrix at weight ratios of 2:1, 1:1, and 1:2. The formulations showed stability under an acidic vaginal environment (according to ICH Q1A(R2). The amount of baicalein and wogonin released from the formulation (2:1) in vitro was 84.60% and 28.41%, respectively, after 24 h of testing. The formulated preparations showed higher antifungal activity compared to the pure extract (p < 0.05). The binary system containing the freeze-dried extract of S. baicalensis radix with chitosan mixed in a weight ratio of 2:1 showed a particularly beneficial effect on the vaginal microbiome. The most sensitive strain was C. parapsilosis. The therapeutic effect of the 2:1 binary system was comparable to that of metronidazole and clindamycin (p < 0.05). The authors suggest that a chitosan-based extract of S. baicalensis radix may show therapeutic potential in the treatment of vaginal infections, particularly vulvovaginal candidiasis.
Paeonia suffruticosa is a species with its natural occurrence in Asia (growing mainly in the mountains of Eastern, Central, and Southwestern China). Other authors believe that this plant is a hybrid; hence, its origin is difficult to determine [116]. Jia et al. [90] investigated the efficacy of a formulation of carboxymethyl chitosan (CMCS) with the leaf extract of P. suffruticosa (PLE) in the treatment of vaginitis in a mouse model. The authors confirmed by SEM, XRD, and FTIR the presence of hydrogen bonds between CMCS and PLE of the developed hydrogel and the stability of the structure of the formulation, which increased with increasing PLE concentration (0.5, 1.0, 1.5, and 2 wt% PLE). The hydrogel was characterized by a porous structure with a three-dimensional network. In a pharmaceutical availability study (in vitro), 92% of the initial PLE dose was released after 12 h, while the complete release was observed after 3 days of testing. Measurements using oscillatory rheology confirmed that the elastic modulus G’ was dominant at the measured frequencies, indicating that the formulation exhibited the properties of an elastic solid gel. In the swelling test, the swelling rate of the hydrogel increased with increasing PLE concentration and was 300–400% (pH = 7.4). On the other hand, in the DPPH and ABTS free radical scavenging method in vitro, the antioxidant activity of the hydrogel was confirmed, which also increased with increasing PLE concentration. At the highest PLE concentration, the highest bacteriostatic index (>96%) was also recorded against bacteria causing vaginitis (i.e., S. aureus, B. streptococcus, S. epidermidis, E. coli, C. albicans, and MRSA). The study confirmed that CMCS-PLE hydrogel effects restore the balance of the vaginal bacterial flora, making it effective in eliminating the bacteria responsible for mixed infectious vaginitis (p < 0.0001).

6.1.4. Africa

Pelargonium graveolens is native to South Africa [117]. dos Santos et al. [84] investigated the efficacy of Pelargonium graveolens essential oils from Egypt, South Africa (two samples), China, Reunion Island (France), Albania, and Brazil in the treatment of Candida spp. fungal infections of the vagina and vulva. A hydrogel-thickened nanoemulsion was prepared by mechanical mixing, combining essential oils (10%) with chitosan (2%). It was hypothesized that the mechanism of action of the active substances involves electrostatic interactions between the components of the formulation and the fungal cell membrane and a pro-oxidant effect on the microorganisms. In vitro results showed that the highest efficacy against Candida spp. was obtained with one of the samples from South Africa (MIC 128–256 μg/mL). Similar results were obtained with essential oils from France and China. The most sensitive species to essential oils were C. parapsilosis, followed by C. tropicalis, with MIC values of 128 μg/mL and 256 μg/mL, respectively. Samples from Brazil and South Africa showed little ability to inhibit the growth of Candida species with MICs of 512 μg/mL for most isolates and strains. The results obtained were statistically significant at p < 0.05.

6.1.5. Australia and Oceania

Melaleuca alternifolia (known as tea tree) is a species endemic to the myrtle family found in Australia (southern Queensland and New South Wales) [118]. Hammer et al. [73] investigated tea tree essential oil, as well as intra-vaginal products containing this oil against Candida spp. Melaleuca alternifolia is an Australian native plant of the family Myrtaceae. From the leaves of this tree, essential oil is extracted by steam distillation, which has long been used as an effective antimicrobial agent [118]. A study by Hammer [73] confirmed that Candida spp. (C. albicans, C. glabrata, C. parapsilosis, and other species) are sensitive (at low concentrations ≤ 0.5%) to tea tree essential oil. The authors also tested M. alternifolia essential oil-based products (gel 3%, gel 10%, and pessary 10%), confirming their in vitro anticandidal activity and indicating their potential use in vaginal candidiasis therapy. All tested products showed MICs (0.12–0.25%) and MFCs (0.25–0.5%) similar to non-formulated M. alternifolia volatile oil (MIC and MFC were ≤0.25%) for C. albicans ATCC 10231. However, further clinical trials are needed to confirm the efficacy of tea tree oil and products containing this anti-yeast active ingredient in vivo. Kola-Mustapha et al. [88] evaluated the antifungal efficacy of M. alternifolia and C. flexuosus against vaginal strains of Candida albicans. The carrier of the oils was an emulgel based on xanthine gum (XG) and guar gum (3:2, 2:3, 4:1, 1:4). The dispersing phase was a mixture of Smix (Tween 80/32% and Span 60/68% with coconut oil). The synergistic effects of the essential oils were investigated, and the therapeutic potential of each oil was separately assessed. The minimum inhibitory concentration (MIC) of the essential oils was 50 µL/mL and 25 µL/mL for M. alternifolia and C. flexuosus, respectively. An analysis of the fractional inhibitory concentration index (FICI) values showed that the combination of the two oils in a ratio of 75:25 (C. flexuosus:M. alternifolia) gave the highest antifungal activity. A strong synergistic effect of the oils was obtained with FICI (fractional inhibitory concentration index) values of 0.4 and 0.5. The viscosity of the developed emulsion was 8946.3 ± 8.8 mPas, while pH = 3.76–3.78. The formulation remained stable for one month, indicating the compatibility of the essential oils with the emulgel-type base. The authors suggest a high efficacy of the emulgel in inhibiting the growth of C. albicans.

6.2. Clinical Research

Global Coverage

Clinical studies on the efficacy of hydrogels containing plant raw materials have been carried out on plant species with a wide global range. Myrtus communis is native to areas of the Mediterranean basin. It is also found in North Africa, Europe, and West Asia. The range of Berberis vulgaris includes most of continental Europe, as well as the Caucasus, northwestern Iran, and northern Anatolia. Thymus vulgaris is a plant found in Europe, Asia, and northwestern Africa. Syzygium aromaticum is mainly found in Indonesia [119,120,121]. Masoudi’s team [93] compared the therapeutic efficacy of gels containing Berberis vulgaris 5% and Myrtus communis 2% extracts in a metronidazole base versus a gel containing metronidazole 0.75%. By analyzing the package leaflet for metronidazole vaginal gel 0.75%, we confirmed that the hydrogels were formulated on a Carbopol base. The 120 patients were divided into three groups (Myrtus communis in metronidazole base/group A; Berberis vulgaris in metronidazole base/group B; metronidazole alone/group C; each group had 40 patients). The duration of therapy was 7 days. After this time, the treatment of infection was found to be highly effective in patients in groups A and B compared with the treatment of patients in group C (p < 0.001). Furthermore, there was no significant difference between groups A and B (p = 0.18). Thirty percent of patients treated with metronidazole gel alone experienced a recurrence of infection within three weeks. No recurrence of bacterial vaginosis was observed in patients who used Berberis vulgaris in a metronidazole base and Myrtus communis in a metronidazole base. No serious side effects or recurrences were confirmed in treated patients.
The same authors in subsequent clinical studies [94,95] confirmed the high therapeutic efficacy of Berberis vulgaris 5% metronidazole-based vaginal hydrogel (group A/40 patients) and Myrtus communis 2% metronidazole-based vaginal hydrogel (group B/40 patients) compared with metronidazole 0.75% vaginal gel (group C/40 patients), p < 0.001 and p < 0.05, respectively. Extracts were prepared by percolation with 70% ethanol. The authors concluded that the formulations developed increased the efficacy of the treatment of bacterial vaginitis. Patients did not experience serious side effects during treatment. The therapeutic potential of Berberis vulgaris was confirmed by the Shabanian team [94]. Patients with bacterial vaginitis were treated vaginally for 5 days with metronidazole hydrogel 0.75% (40 patients/group A) and Berberis vulgaris hydrogel 5% (40 patients/group B), respectively. Patients diagnosed with an allergy to barberry were excluded from the study. Berberis vulgaris hydrogel 5% showed higher therapeutic efficacy (p = 0.001) and improvement in symptoms of irritation, dyspareunia, and dysuria (p < 0.05).
Murina et al. [96] evaluated the therapeutic efficacy of a vaginal gel containing extracts of Thymus vulgaris and Eugenia caryophyllus in the treatment of bacterial vaginitis and vulvovaginal candidiasis. In parallel, two strains of lactobacilli (Lactobacillus fermentum LF10 and Lactobacillus plantarum LP02) were administered to the patients as extended-release vaginal capsules. The study involved 209 female patients from thirty-eight centers. Of these, 100 were diagnosed with bacterial vaginosis (BV), 82 with vulvovaginal candidiasis (VVC), and 27 had recurrent vulvovaginal candidiasis disease (RVVC). After treatment, microbiological evaluation was performed, which confirmed an adequate status in 80.0% of patients with BV, 62.5% with VVC, and 100.0% with RVVC. Clinical symptoms resolved in 83.9% of cases with BV, 81.6% with VVC, and 63.0% with RVVC (p = 0.001). All patients tolerated the prescribed treatment well. The authors point to the lack of randomization, the open-label nature of the study, and the small sample size for RVVC (23 patients) as limitations of the study. Furthermore, they suggest that they could not exclude a placebo effect.

6.3. Potential of Antipathogenic Activities of Plants

The wide range of anti-bacterial/bacteriostatic and antifungal activities of plant-derived substances is due to their diverse chemical composition and a broad spectrum of biological activity. These compounds exhibit the ability to penetrate the cell wall and membrane of microorganisms, causing disruption of their integrity. For example, terpenes cause coagulation of the cytoplasm and permeabilization of the bacterial cell membrane. This results in the loss of H+ and K+ ions, the disruption of normal ion pump function, a decrease in membrane potential, and a decrease in intracellular ATP levels [122,123]. The bactericidal action of polyphenols results in the degradation of the pathogen’s cell walls, interacting directly with cytoplasmic membranes (disrupting them), damaging membranes and proteins, disrupting enzymatic reaction mechanisms, and affecting both RNA and DNA synthesis [124,125]. The antifungal activity of natural compounds is in turn due to their ability to damage the integrity and rigidity of the fungal cell wall. Cracking of the cell wall and leakage of cytoplasm may be a consequence of their effect on the action of enzymes involved in cell wall synthesis. Some natural compounds (e.g., thymol, limonene) inhibit cell wall synthases [126].

7. Plant Raw Materials—Requirements and Limitations on Their Use

The content of active substances in a plant is influenced by, among other things, geographical location, time of year, and time of day, and it is a species-specific issue. It has been found, for example, that plants harvested in early spring and summer contain the highest alkaloid content. The highest concentrations of essential oils and glycosides are observed in plants harvested in the late morning and early afternoon [127,128,129]. However, it should be emphasized that plant raw materials should come from cultivation or natural sites, and their specific harvesting requirements are defined by the specific monograph of the Polish Pharmacopoeia (FP), the European Pharmacopoeia (Ph. Eur), another country’s Pharmacopoeia, and the European Medicines Agency’s Guidelines. FP/Ph. Eur. distinguishes between three types of extracts, namely extracts standardized for active ingredients (in which limits are defined for the content of the active ingredient/group of ingredients with established therapeutic activity), quantified extracts (containing a precisely defined amount of active markers), and other extracts (defined by a precise description of the manufacturing process and quality specifications) [130,131].
Plant extracts exhibit volatility, high sensitivity to environmental factors, and reduced stability. Hydrogel matrices are effective carriers to minimize these limitations. Plant-based hydrogels are biocompatible and biodegradable with optimal physicochemical parameters [132]. Incorporating plant materials into polymer matrices maintains their biological activity and protects them from degradation. A significant limitation of the technology for preparing this drug form is the plant extract’s variable chemical composition, which depends on the ecological conditions. The qualitative and quantitative composition of the raw material is influenced by external factors, including the age and variety of the plant, the type and quality of the soil, climatic conditions (length of the growing season, sunshine, precipitation), developmental stage, genetic factors, the harvesting method, storage method, flower color, and the extraction method used [132,133]. The plant material intended for pharmaceutical purposes shows variable quality at the stage of its preparation, so it must be standardized for the content of the active ingredient(s) before the hydrogel is prepared. Standardization ensures the adequate efficacy and therapeutic reproducibility of plant drugs.
Herbal extracts are complex mixtures of many active compounds that may interact with other medicines taken by patients. It is suggested that despite their standardization to one/some components, there may be variability in the other compounds present in the raw material. Bioactive components may affect metabolic enzymes, often implicated in drug–drug interactions. Modarai et al. [134] investigated the cytochrome P450 inhibitory effects of coneflower preparation. They chose a standardized, Swiss-registered extract of Echinacea purpurea (L.) for evaluation. The authors found that its inhibitory effect varied and depended on the alkylamide content. The CYP3A4 enzyme was the most sensitive to inhibition, while CYP2D6 was the least sensitive. Another study [135] confirmed the CYP3A inhibitory effect of Chinese-specific plants (Andrographis paniculata, Acacia catechu, Arctium lappa, Bupleurum marginatum, Spatholobus suberectus, Dysosma versipellis) due to the presence of polyphenolics. The authors concluded that the raw materials studied may interfere with the metabolism of concurrently administered herbs and drugs, metabolized by CYP3A4. Decreased metabolism of the drug can lead to accumulation in the body and consequently to the development of toxicity. A toxic reaction may also develop as a consequence of the additive effect of the herb and the drug. The study indicates that caution should be exercised when using herbal preparations with other drugs.
Some studies confirm the adverse effects of botanical preparations, which are related to their allergenic effects. The most common allergenic botanicals include German/Roman chamomile (Chamomilla recutita, Chamaemelum nobile), arnica (Arnica montana), Echinacea, marigold (Calendula officinalis), elecampane (Inula helenium), and tea tree oil [136,137,138]. Some authors suggest caution during the use of botanicals. It is recommended that patients perform a patch test on a small area of skin to check for any hypersensitivity or allergic reaction [139].

8. Conclusions

Vaginal hydrogels containing plant material show potential in the treatment of vaginal and vulvar infections. They could be considered for use as part of adjunctive therapy in accordance with pharmaceutical regulations. However, due to the small number of clinical trials conducted to date, it is suggested that research in this area should continue. Further studies should also focus on determining the optimal API dosing regimen. It is also important to study the interaction between the hydrogel carrier and the bioactive compound to optimize release kinetics.

Author Contributions

Conceptualization, A.O.-C. and M.K.; literature review, A.O.-C., M.M. and T.B.; writing—original draft preparation, A.O.-C., M.M. and T.B.; writing—review and editing, A.O.-C., M.M. and M.K.; funding acquisition, A.O.-C. All authors have read and agreed to the published version of the manuscript.

Funding

The research project was financed by the Medical University of Silesia in Katowice, no. BNW-1–038/K/4/F.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Capuozzo, M.; Zovi, A.; Langella, R.; Ottaiano, A.; Cascella, M.; Scognamiglio, M.; Ferrara, F. Optimizing Antibiotic Use: Addressing Resistance through Effective Strategies and Health Policies. Antibiotics 2024, 13, 1112. [Google Scholar] [CrossRef] [PubMed]
  2. Sheppard, C. Treatment of vulvovaginitis. Aust. Prescr. 2020, 43, 195–199. [Google Scholar] [CrossRef] [PubMed]
  3. Hildebrand, J.P.; Carlson, K.; Kansagor, A.T. Vaginitis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK470302/ (accessed on 6 October 2024).
  4. Brown, H.; Drexler, M. Improving the Diagnosis of Vulvovaginitis: Perspectives to Align Practice, Guidelines, and Awareness. Popul. Health Manag. 2020, 23, S3–S12. [Google Scholar] [CrossRef] [PubMed]
  5. Kairys, N.; Carlson, K.; Garg, M. Bacterial Vaginosis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK459216/ (accessed on 6 October 2024).
  6. Jeanmonod, R.; Chippa, V.; Jeanmonod, D. Vaginal Candidiasis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/sites/books/NBK459317/ (accessed on 6 October 2024).
  7. Schumann, J.A.; Plasner, S. Trichomoniasis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/sites/books/NBK534826/ (accessed on 6 October 2024).
  8. Obiero, J.; Rulisa, S.; Ogongo, P.; Wiysonge, C.S. Nifuratel-Nystatin combination for the treatment of mixed infections of bacterial vaginosis, vulvovaginal candidiasis, and trichomonal vaginitis. Cochrane Database Syst. Rev. 2018, 2018, CD013012. [Google Scholar] [CrossRef]
  9. Kuś, J.; Partyka, A.; Hamm, D.; Thumm, A. Application of clinical aromatherapy in the treatment of vaginal infections. Herbalism 2021, 1, 73–90. [Google Scholar]
  10. Mazzei, R.; Genovese, C.; Magariello, A.; Patitucci, A.; Russo, G.; Tagarelli, G. Plants in Menstrual Diseases: A Systematic Study from Italian Folk Medicine on Current Approaches. Plants 2024, 13, 589. [Google Scholar] [CrossRef]
  11. Khadim, S.; Malik, K.; Kazmi, A.; Sultana, T.; Ali, A.; Mehmood, K.; Ul Hassan, R.; Nasir Bashir, M.; Ali, M. Folklore use of medicinal plants for the treatment of gynecological diseases in Pakistan—A review. Heliyon 2024, 10, 34869. [Google Scholar] [CrossRef]
  12. Grzesik-Gąsior, J.; Bień, A.; Pieczykolan, A. Phyotherapy in gynecological infections as natural support in the treatment proces. Pielęgniarstwo XXI Wieku 2018, 17, 69–73. [Google Scholar] [CrossRef]
  13. Król, S.K.; Skalicka-Woźniak, K.; Kandefer-Szerszeń, M.; Stepulak, A. The biological and pharmacological activity of essential oils in the treatment and prevention of infectious diseases. Postep. Hig. Med. Dosw. 2013, 67, 1000–1007. [Google Scholar] [CrossRef]
  14. Balamurugan, S.; Vijayakumar, S.; Prabhu, J.E.; Yabesh, M. Traditional plants used for the treatment of gynaecological disorders in Vedaranyam taluk, South India—An ethnomedicinal survey. J. Tradit. Complement. Med. 2018, 8, 308–323. [Google Scholar] [CrossRef]
  15. Das, D.C.; Sinha, N.K.; Das, M. The use of medicinal plants for the treatment of gynaecological disorders in the Eastern parts of India. J. Obstet. Gynecol. India 2015, 2, 16–27. [Google Scholar]
  16. Kashani, L.; Hajiaghaee, R.; Akhondzadeh, S. Herbal Medicine in the Treatment of Premenstrual Syndromes. J. Med. Plants 2011, 10, 1–5. [Google Scholar]
  17. Okpanyi, S.N.; Ezeukwu, G.C. Anti-inflammatory and antipyretic activities of Azadirachta indica. Planta Med. 1981, 41, 34–39. [Google Scholar] [CrossRef] [PubMed]
  18. Regev, G.; Patel, S.K.; Moncla, B.J.; Twist, J.; Devlin, B.; Rohan, L.C. Novel Application of Hot Melt Extrusion for the Manufacturing of Vaginal Films Containing Microbicide Candidate Dapivirine. AAPS PharmSciTech 2019, 20, 239. [Google Scholar] [CrossRef]
  19. Thapa, R.; Gurung, S.; Parat, M.-O.; Parekh, H.S.; Pandey, P. Application of Sol–Gels for Treatment of Gynaecological Conditions—Physiological Perspectives and Emerging Concepts in Intravaginal Drug Delivery. Gels 2022, 8, 99. [Google Scholar] [CrossRef]
  20. Osmałek, T.; Froelich, A.; Jadach, B.; Tatarek, A.; Gadziński, P.; Falana, A.; Gralińska, K.; Ekert, M.; Puri, V.; Wrotyńska-Barczyńska, J.; et al. Recent Advances in Polymer-Based Vaginal Drug Delivery Systems. Pharmaceutics 2021, 13, 884. [Google Scholar] [CrossRef]
  21. Palmeira-de-Oliveira, R.; Palmeira-de-Oliveira, A.; Martinez-de-Oliveira, J. New strategies for local treatment of vaginal infections. Adv. Drug Deliv. Rev. 2015, 92, 105–122. [Google Scholar] [CrossRef]
  22. Leyva-Gómez, G.; Prado-Audelo, D.; Ortega-Peña, S.; Mendoza-Muñoz, N.; Urbán-Morlán, Z.; González-Torres, M.; Carmen, G.D.; Figueroa-González, G.; Reyes-Hernández, O.D.; Cortés, H.; et al. Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities. Pharmaceutics 2019, 11, 217. [Google Scholar] [CrossRef]
  23. Ostróżka-Cieślik, A. The Potential of Pharmaceutical Hydrogels in the Formulation of Topical Administration Hormone Drugs. Polymers 2022, 14, 3307. [Google Scholar] [CrossRef]
  24. Salehi, T.; Raeisi Estabragh, M.A.; Salarpour, S.; Ohadi, M.; Dehghannoudeh, G. Absorption Enhancer Approach for Protein Delivery by Various Routes of Administration: A Rapid Review. J. Drug Target. 2023, 31, 950–961. [Google Scholar] [CrossRef]
  25. dos Santos, A.M.; Carvalho, S.G.; Araujo, V.H.S.; Carvalho, G.C.; Gremião, M.P.D.; Chorilli, M. Recent Advances in Hydrogels as Strategy for Drug Delivery Intended to Vaginal Infections. Int. J. Pharm. 2020, 590, 119867. [Google Scholar] [CrossRef] [PubMed]
  26. Siafaka, P.I.; Gündoğdu, E.A.; Cağlar, E.S.; Özgenç, E.; Gonzalez-Alvarez, M.; Gonzalez-Alvarez, I.; Okur, N.Ü. Polymer Based Gels: Recent and Future Applications in Drug Delivery Field. Curr. Drug Deliv. 2023, 20, 1288–1313. [Google Scholar] [CrossRef] [PubMed]
  27. Caramella, C.M.; Rossi, S.; Ferrari, F.; Bonferoni, M.C.; Sandri, G. Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv. Drug Deliv. Rev. 2015, 92, 39–52. [Google Scholar] [CrossRef]
  28. Cook, M.T.; Brown, M. Polymeric gels for intravaginal drug delivery. J. Control. Release 2018, 270, 145–157. [Google Scholar] [CrossRef] [PubMed]
  29. Binaymotlagh, R.; Hajareh Haghighi, F.; Chronopoulou, L.; Palocci, C. Liposome–Hydrogel Composites for Controlled Drug Delivery Applications. Gels 2024, 10, 284. [Google Scholar] [CrossRef]
  30. Xiao, Y.; Ma, T.; Wu, H.; Su, Q.; Zhou, Y.; Zhou, B.; Yang, K.; Pu, Z.; Feng, W.; Yong, X.; et al. Research progress of hydrogels in the prevention of pelvic inflammatory disease. MedComm Biomater. Appl. 2024, 3, e100. [Google Scholar] [CrossRef]
  31. Borotová, P.; Galovičová, L.; Vukovic, N.L.; Vukic, M.; Tvrdá, E.; Kačániová, M. Chemical and Biological Characterization of Melaleuca alternifolia Essential Oil. Plants 2022, 11, 558. [Google Scholar] [CrossRef]
  32. Kędzia, B.; Alkiewicz, J.; Han, S. Significance of tea tree oil in phytotherapy. Part I. Composition of essential oil and its biological properties. Post. Fitoter. 2000, 2, 36–40. [Google Scholar]
  33. Kania-Dobrowolska, M.; Baraniak, J. Trigonella foenum-graecum seeds in treatment of metabolic syndrome. Herba Pol. 2020, 66, 48–55. [Google Scholar] [CrossRef]
  34. Patela, S.M.; Nagulapalli Venkatab, K.C.; Bhattacharyyac, P.; Sethid, G.; Bishayeeb, A. Potential of neem (Azadirachta indica L.) for prevention and treatment of oncologic diseases. Semin. Cancer Biol. 2016, 40–41, 100–115. [Google Scholar] [CrossRef]
  35. Herrera-Calderon, O.; Ejaz, K.; Wajid, M.; Shehzad, M.; Tinco-Jayo, J.A.; Enciso-Roca, E.; Franco-Quino, C.; Yuli-Posadas, R.Á.; Chumpitaz-Cerrate, V. Azadirachta indica: Antibacterial Activity of Neem against Different Strains of Bacteria and their Active Constituents as Preventive in Various Diseases. Pharmacog. J. 2019, 11, 1597–1604. [Google Scholar] [CrossRef]
  36. Aisa, H.A.; Xin, X.; Tang, D. Chemical constituents and their pharmacological activities of plants from Cichorium genus. Chin. Herb. Med. 2020, 12, 224–236. [Google Scholar] [CrossRef]
  37. Wu, H.; Liu, Z.; Zhang, Y.; Gao, B.; Li, Y.; He, X.; Sun, J.; Choe, U.; Chen, P.; Blaustein, R.A.; et al. Chemical Composition of Turmeric (Curcuma longa L.) Ethanol Extract and Its Antimicrobial Activities and Free Radical Scavenging Capacities. Foods 2024, 13, 1550. [Google Scholar] [CrossRef] [PubMed]
  38. Niranjan, A.; Prakash, D. Chemical constituents and biological activities of turmeric (Curcuma longa L.)—A review. J. Food Sci. Technol. 2008, 45, 109–116. [Google Scholar]
  39. Kazemi, M. Phytochemical Composition of Thymus vulgaris L. Essential Oil. J. Essent. Oil Bear. Plants 2015, 18, 751–753. [Google Scholar] [CrossRef]
  40. Usha Kiran Reddy, T.; Sindhu, G.; Rajesh, S.; Aruna, B. A review on Thymus vulgaris for its reported pharmacological activities and major chemical constituents. IAJPS 2017, 4, 1372–1376. [Google Scholar] [CrossRef]
  41. Nurzyńska-Wierdak, R.; Chrapek, A. Genus Thymus L.—Aromatic and medicinal values. Overview of selected species. Ann. Hortic. 2022, 31, 33–53. [Google Scholar] [CrossRef]
  42. Hannan, M.A.; Rahman, M.A.; Sohag, A.A.M.; Uddin, M.J.; Dash, R.; Sikder, M.H.; Rahman, M.S.; Timalsina, B.; Munni, Y.A.; Sarker, P.P.; et al. Black Cumin (Nigella sativa L.): A Comprehensive Review on Phytochemistry, Health Benefits, Molecular Pharmacology, and Safety. Nutrients 2021, 13, 1784. [Google Scholar] [CrossRef]
  43. Kooti, W.; Hasanzadeh-Noohi, Z.; Sharafi-Ahvazi, N.; Asadi-Samani, M.; Ashtary-Larky, D. Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa). Chin. J. Nat. Med. 2016, 14, 732–745. [Google Scholar] [CrossRef]
  44. Argon, Z.U.; Gokyer, A. Determination of Physicochemical Properties of Nigella sativa Seed Oil from Balıkesir Region, Turkey. Chem. Process Eng. Res. 2016, 41, 43–46. [Google Scholar]
  45. Bilel, H.; Yahia, M.; Moustafa, S.M.N. An overview of chemical composition and fungicidal activity of Olive (Olea europea L.) Leaf Extract. Egypt. J. Chem. 2023, 66, 303–311. [Google Scholar] [CrossRef]
  46. Wroniak, M.; Maszwska, M. Olive oil in the Mediterranean diet. Food. Sci. Technol. Qual. 2011, 5, 26–36. [Google Scholar] [CrossRef]
  47. Saoulajan, C.; Boujida, N.; El Mihyaoui, A.; El Baakili, A.; Merae Alshahrani, M.; Lee, L.H.; Bouyahya, A. Phytochemistry, pharmacological investigations, industrial applications, and encapsulation of Thymbra capitata L., a review. Trends Food Sci. Technol. 2022, 129, 463–491. [Google Scholar] [CrossRef]
  48. Benkhayal, F.A.; Al-Gazwi, S.M.; Ramesh, S.; Kumar, S. Biochemical studies on the effect of volatile oil of thymus capitatus in alloxan-induced diabetic rats. Curr. Trends Biotechnol. Pharm. 2010, 4, 519–525. [Google Scholar]
  49. Taskın, T.; Çam, M.E.; Bulut, G.; Hazar-Yavuz, A.N.; Kabasakal, L.; Bitis, L. Antioxidant and anti-inflammatory activities of Phlomis pungens and Coridothymus capitatus. MARMARA Pharm. J. 2018, 22, 80–85. [Google Scholar] [CrossRef]
  50. de Freitas Araújo, M.G.; Pacífico, M.; Vilegas, W.; Dos Santos, L.C.; Icely, P.A.; Miró, M.S.; Scarpa, M.V.C.; Bauab, T.M.; Sotomayor, C.E. Evaluation of Syngonanthus nitens (Bong.) Ruhl. extract as antifungal and in treatment of vulvovaginal candidiasis. Med. Mycol. 2013, 51, 673–682. [Google Scholar] [CrossRef]
  51. Siqueira de Oliveira, A.P.; Ferreira de Sousa, J.; Aparecido da Silva, M.; Hilario, F.; Aparecida Resende, F.; Santoro de Camargo, M.; Vilegas, W.; Campaner dos Santos, L.; Aparecida Varanda, E. Estrogenic and chemopreventive activities of xanthones and flavones of Syngonanthus (Eriocaulaceae). Steroids 2013, 78, 1053–1063. [Google Scholar] [CrossRef]
  52. Souza-Moreira, T.M.; Queiroz-Fernandes, G.M.; Pietro, R.C.L.R. Stryphnodendron Species Known as “Barbatimão”: A Comprehensive Report. Molecules 2018, 23, 910. [Google Scholar] [CrossRef]
  53. Chen, F.; Al-Ahmad, H.; Joyce, B.; Zhao, N.; Kollner, T.G.; Degenhardt, J.; Neal Stewart, C., Jr. Within-plant distribution and emission of sesquiterpenes from Copaifera officinalis. Plant Physiol. Biochem. 2009, 47, 1017–1023. [Google Scholar] [CrossRef]
  54. Jaradat, N.; Hawash, M.; Qadi, M.; Abualhasan, M.; Odetallah, A.; Qasim, G.; Awayssa, R.; Akkawi, A.; Abdullah, I.; Al-Maharik, N. Chemical Markers and Pharmacological Characters of Pelargonium graveolens Essential Oil from Palestine. Molecules 2022, 27, 5721. [Google Scholar] [CrossRef]
  55. Boukhris, M.; Simmonds, M.S.J.; Sayadi, S.; Bouaziz, M. Chemical Composition and Biological Activities of Polar Extracts and Essential Oil of Rose-scented Geranium, Pelargonium graveolens. Phytother. Res. 2013, 27, 1206–1213. [Google Scholar] [CrossRef] [PubMed]
  56. Fabri, R.L.; Garcia, R.A.; Rodrigues Florêncio, J.; de Castro Campos Pinto, N.; de Oliveira, L.G.; Kopke Aguiar, J.A.; Ribeiro, A.; Scio, E. Anti-inflammatory and antioxidative effects of the methanolic extract of the aerial parts of Mitracarpus frigidus in established animal models. J. Pharm. Pharmacol. 2014, 66, 722–732. [Google Scholar] [CrossRef] [PubMed]
  57. Lemos, A.S.D.O.; Campos, L.M.; Souza, T.D.F.; Paula, P.D.L.; Granato, J.D.T.; da Silva, J.V.G.; Aragão, D.M.; Rocha, V.N.; Coimbra, E.S.; Fabri, R.L. Pharmacological investigation of antioxidant and anti-inflammatory activities of aqueous extract from Mitracarpus frigidus (Rubiaceae). J. Pharm. Pharmacol. 2022, 74, 750–760. [Google Scholar] [CrossRef]
  58. Liao, H.; Ye, J.; Gao, L.; Liu, Y. The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review. Biomed. Pharmacother. 2021, 133, 110917. [Google Scholar] [CrossRef] [PubMed]
  59. Gao, B.; Zhu, H.; Liu, Z.; He, X.; Sun, J.; Li, Y.; Wu, X.; Pehrsson, P.; Zhang, Y.; Yu, L. Chemical Compositions of Scutellaria baicalensis Georgi. (Huangqin) Extracts and Their Effects on ACE2 Binding of SARS-CoV-2 Spike Protein, ACE2 Activity, and Free Radicals. Int. J. Mol. Sci. 2024, 25, 2045. [Google Scholar] [CrossRef]
  60. de Souza Pereira, J.J.; Pereira, A.P.C.; Jandú, J.J.B.; da Paz, J.A.; dos Santos, C.; Correia, M.T.; de Azevêdo Silva, J. Commiphora leptophloeos Phytochemical and Antimicrobial Characterization. Front. Microbiol. 2017, 8, 52. [Google Scholar] [CrossRef]
  61. Bhatnagar, A. Chemical constituents and biological activities of Cymbopogon flexuosus (Lemon Grass). J. Res. Chem. 2023, 4, 91–95. [Google Scholar] [CrossRef]
  62. Aubert, C.; Chalot, G. Chemical Batiha composition, bioactive compounds, and volatiles of six table grape varieties (Vitis vinifera L.). Food Chem. 2018, 240, 524–533. [Google Scholar] [CrossRef]
  63. Giraldo-Silva, L.; Ferreira, B.; Rosa, E.; Dias, A.C.P. Opuntia ficus-indica Fruit: A Systematic Review of Its Phytochemicals and Pharmacological Activities. Plants 2023, 12, 543. [Google Scholar] [CrossRef]
  64. Lei, G.; Song, C.; Wen, X.; Gao, G.; Qi, Y. Chemical Diversity and Potential Target Network of Woody Peony Flower Essential Oil from Eleven Representative Cultivars (Paeonia × suffruticosa Andr.). Molecules 2022, 27, 2829. [Google Scholar] [CrossRef]
  65. Wang, J.; Wu, G.; Chu, H.; Wu, Z.; Sun, J. Paeonol Derivatives and Pharmacological Activities: A Review of Recent Progress. Mini Rev. Med. Chem. 2020, 20, 466–482. [Google Scholar] [CrossRef] [PubMed]
  66. Moghadamtousi, S.Z.; Fadaeinasab, M.; Nikzad, S.; Mohan, G.; Ali, H.M.; Abdul Kadir, H. Annona muricata (Annonaceae): A Review of Its Traditional Uses, Isolated Acetogenins and Biological Activities. Int. J. Mol. Sci. 2015, 16, 15625–15658. [Google Scholar] [CrossRef]
  67. Caputo, L.; Capozzolo, F.; Amato, G.; De Feo, V.; Fratianni, F.; Vivenzio, G.; Nazzaro, F. Chemical composition, antibiofilm, cytotoxic, and anti-acetylcholinesterase activities of Myrtus communis L. leaves essential oil. BMC Complement. Med. Ther. 2022, 22, 142. [Google Scholar] [CrossRef] [PubMed]
  68. Ivan, I.M.; Olaru, O.T.; Popovici, V.; Chițescu, C.L.; Popescu, L.; Luță, E.A.; Ilie, E.I.; Brașoveanu, L.I.; Hotnog, C.M.; Nițulescu, G.M.; et al. Antioxidant and Cytotoxic Properties of Berberis vulgaris (L.) Stem Bark Dry Extract. Molecules 2024, 29, 2053. [Google Scholar] [CrossRef] [PubMed]
  69. El-Saber, G.; Alkazmi, L.M.; Wasef, L.G.; Beshbishy, A.M.; Nadwa, E.H.; Rashwan, E.K. Syzygium aromaticum L. (Myrtaceae): Traditional Uses, Bioactive Chemical Constituents, Pharmacological and Toxicological Activities. Biomolecules 2020, 10, 202. [Google Scholar] [CrossRef]
  70. Luthfianti, H.R.; Waresindo, W.X.; Edikresnha, D.; Hapidin, D.A.; Noor, F.A.; Elfahmi, E.; Khairurrijal, K. Bioactive Compounds-Loaded Polyvinyl Alcohol Hydrogels: Advancements in Smart Delivery Media for Biomedical Applications. Mater. Res. Express 2024, 11, 062002. [Google Scholar] [CrossRef]
  71. Pelin, I.M.; Silion, M.; Popescu, I.; Rîmbu, C.M.; Fundueanu, G.; Constantin, M. Pullulan/Poly(vinyl alcohol) Hydrogels Loaded with Calendula officinalis Extract: Design and In Vitro Evaluation for Wound Healing Applications. Pharmaceutics 2023, 15, 1674. [Google Scholar] [CrossRef]
  72. Tabata, Y.; Nagano, A.; Ikada, Y. Biodegradation of hydrogel carrier incorporating fibroblast growth factor. Tissue Eng. 1999, 5, 127–138. [Google Scholar] [CrossRef]
  73. Hammer, K.A.; Carson, C.F.; Riley, T.V. In vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree oil products, against Candida spp. J. Antimicrob. Chemother. 1998, 42, 591–595. [Google Scholar] [CrossRef]
  74. Chopra, S.; Motwani, S.K.; Iqbal, Z.; Talengaonkar, S.; Ahmad, F.J.; Khar, R.K. Optimization of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. Eur. J. Pharm. Biopharm. 2007, 67, 120–131. [Google Scholar] [CrossRef]
  75. das Neves, J.; Pinto, E.; Amaral, M.H.; Bahia, M.F. Antifungal activity of a gel containing Thymus vulgaris essential oil against Candida species commonly involved in vulvovaginal candidosis. Pharm. Biol. 2009, 47, 151–153. [Google Scholar] [CrossRef]
  76. Sangi, S.; Harsha, S.; Tasleem-ur-Rasool, S.; Asif, A.H. Formulation and evaluation of mucoadhesive Nigalla sativa and Olive oils for vaginal infections. Pharm. Lett. 2011, 3, 39–46. [Google Scholar]
  77. Palmeira-de-Oliveira, A.; Palmeira-de-Oliveira, R.; Gaspar, C.; Salgueiro, L.; Cavaleiro, C.; Martinez-de-Oliveira, J.; Queiroz, J.; Rodrigues, A. Association of Thymbra capitata essential oil and chitosan (TCCH hydrogel): A putative therapeutic tool for the treatment of vulvovaginal candidosis. Flavour. Fragr. J. 2013, 28, 354–359. [Google Scholar] [CrossRef]
  78. dos Santos Ramos, M.A.; Calixto, G.; de Toledo, L.G.; Bonifácio, B.V.; dos Santos, L.C.; de Almeida, M.T.; Chorilli, M.; Bauab, T.M. Liquid crystal precursor mucoadhesive system as a strategy to improve the prophylactic action of Syngonanthus nitens (Bong.) Ruhland against infection by Candida krusei. Int. J. Nanomed. 2015, 10, 7455–7466. [Google Scholar] [CrossRef] [PubMed]
  79. dos Santos Ramos, M.A.; de Toledo, L.G.; Calixto, G.M.; Bonifácio, B.V.; de Freitas Araújo, M.G.; Dos Santos, L.C.; de Almeida, M.T.; Chorilli, M.; Bauab, T.M. Syngonanthus nitens Bong. (Rhul.)-Loaded Nanostructured System for Vulvovaginal Candidiasis Treatment. Int. J. Mol. Sci. 2016, 17, 1368. [Google Scholar] [CrossRef]
  80. Costa, M.A.; Blainski, A.; Kaplum, V.; de Souza Lima, M.M.; Ueda-Nakamura, T.; Dias Filho, B.P.; de Mello, J.C.P.; Nakamura, C.V. Pharmaceutical topical gel containing proanthocyanidin polymers-rich fraction from Stryphnodendron adstringens. J. Med. Plant Res. 2018, 12, 116–123. [Google Scholar] [CrossRef]
  81. de Freitas, A.L.D.; Kaplum, V.; Rossi, D.C.P.; da Silva, L.B.R.; Melhem, M.S.C.; Taborda, C.P.; de Mello, J.C.P.; Nakamura, C.V.; Ishida, K. Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against Candida spp. isolates and for vaginal candidiasis treatment. J. Ethnopharmacol. 2018, 216, 184–190. [Google Scholar] [CrossRef]
  82. Alves, T.; Souza, J.; Rebelo, M.; Pontes, K.; Santos, C.; Lima, R.; Jozala, A.; Grotto, D.; Severino, P.; Rai, M.; et al. Formulation and evaluation of thermoresponsive polymeric blend as a vaginal controlled delivery system. J. Sol. Gel Sci. Technol. 2018, 86, 536–552. [Google Scholar] [CrossRef]
  83. Morguette, A.E.B.; Bigotto, B.G.; Varella, R.D.L.; Andriani, G.M.; Spoladori, L.F.D.A.; Pereira, P.M.L.; De Andrade, F.G.; Lancheros, C.A.C.; Nakamura, C.V.; Arakawa, N.S.; et al. Hydrogel Containing Oleoresin from Copaifera officinalis Presents Antibacterial Activity against Streptococcus agalactiae. Front. Microbiol. 2019, 10, 2806. [Google Scholar] [CrossRef]
  84. dos Santos, M.K.; Kreutz, T.; Danielli, L.J.; De Marchi, J.G.B.; Pippi, B.; Koester, L.S.; Fuentefria, A.M.; Limberger, R.P. A chitosan hydrogel-thickened nanoemulsion containing Pelargonium graveolens essential oil for treatment of vaginal candidiasis. J. Drug Deliv. Sci. Technol. 2020, 56, 101527. [Google Scholar] [CrossRef]
  85. Campos, L.M.; de Oliveira Lemos, A.S.; da Cruz, L.F.; de Freitas Araújo, M.G.; de Mello Botti, G.C.R.; Júnior, J.L.R.; Rocha, V.N.; Denadai, Â.M.L.; da Silva, T.P.; Tavares, G.D. Development and in Vivo Evaluation of Chitosan-Gel Containing Mitracarpus Frigidus Methanolic Extract for Vulvovaginal Candidiasis Treatment. Biomed. Pharmacother. 2020, 130, 110609. [Google Scholar] [CrossRef]
  86. Chanaj-Kaczmarek, J.; Rosiak, N.; Szymanowska, D.; Rajewski, M.; Wender-Ozegowska, E.; Cielecka-Piontek, J. The Chitosan-Based System with Scutellariae baicalensis radix Extract for the Local Treatment of Vaginal Infections. Pharmaceutics 2022, 14, 740. [Google Scholar] [CrossRef] [PubMed]
  87. Dantas-Medeiros, R.; Marena, G.D.; Araújo, V.H.S.; Neto, F.D.A.B.; Zanatta, A.C.; Lopes, N.P.; Bermejo, P.; Guerra, J.A.; Bedoya, L.M.; Fonseca-Santos, B.; et al. A new hydrogel containing a proanthocyanidin polymer-rich extract of Commiphora leptophloeos for treating vulvovaginal candidiasis: Preclinical results using the alternative model of Galleria mellonella. J. Drug Deliv. Sci. Technol. 2023, 85, 104531. [Google Scholar] [CrossRef]
  88. Kola-Mustapha, A.T.; Aliu, M.H.; Bello, R.H.; Adedeji, O.J.; Ghazali, Y.O. The Formulation and Evaluation of Melaleuca alternifolia Cheel and Cymbopogon flexuosus Linn Essential Oils Emulgel for the Treatment of Vulvovaginal Candidiasis. Gels 2023, 9, 949. [Google Scholar] [CrossRef] [PubMed]
  89. Moraru, A.; Dima, Ș.-O.; Tritean, N.; Oprița, E.-I.; Prelipcean, A.-M.; Trică, B.; Oancea, A.; Moraru, I.; Constantinescu-Aruxandei, D.; Oancea, F. Bioactive-Loaded Hydrogels Based on Bacterial Nanocellulose, Chitosan, and Poloxamer for Rebalancing Vaginal Microbiota. Pharmaceuticals 2023, 16, 1671. [Google Scholar] [CrossRef]
  90. Jia, S.; Huang, S.; Jimo, R.; Axi, Y.; Lu, Y.; Kong, Z.; Ma, J.; Li, H.; Luo, X.; Qu, Y.; et al. In-situ forming carboxymethyl chitosan hydrogel containing Paeonia suffruticosa Andr. leaf extract for mixed infectious vaginitis treatment by reshaping the micro-biota. Carbohydr. Polym. 2024, 339, 122255. [Google Scholar] [CrossRef]
  91. Campos, L.M.; de Oliveira Lemos, A.S.; de Lima Paula, P.; da Rocha, V.N.; de Freitas Araújo, M.G.; Tavares, G.D.; Barradas, T.N.; Nascimento, W.W.G.; Denadai, A.M.L.; de Oliveira, L.F.C.; et al. Exploring the antifungal potential of Annona muricata leaf extract-loaded hydrogel in treating vulvovaginal candidiasis. Colloids Surf. B Biointerfaces 2024, 238, 113919. [Google Scholar] [CrossRef]
  92. Carvalho, G.C.; Domingues, M.N.V.; Marena, G.D.; Mäkilä, E.; Li, J.; Geertsema-Doornbusch, G.; de Andrade, C.R.; Stuart, M.C.; Shahbazi, M.A.; Corrêa, I.; et al. Hybrid Nanoparticles Dual-Loaded with Curcumin and Benzydamine Hydrochloride for the Treatment of Vulvovaginal Candidiasis: From Development to Biological Application In Vitro and In Vivo. Adv. Therap. 2024, 2400342, 2400342. [Google Scholar] [CrossRef]
  93. Masoudi, M.; Miraj, S.; Rafieian-Kopaei, M. Comparison of the effects of Myrtus communis L., Berberis vulgaris and metronidazole vaginal gel alone for the treatment of bacterial vaginosis. J. Clin. Diagn. Res. 2016, 10, QC04–QC07. [Google Scholar] [CrossRef]
  94. Masoudi, M.; Kopaei, M.R.; Miraj, S. Comparison between the efficacy of metronidazole vaginal gel and Berberis vulgaris (Berberis vulgaris) combined with metronidazole gel alone in the treatment of bacterial vaginosis. Eletronic Phys. 2016, 8, 2818–2827. [Google Scholar] [CrossRef]
  95. Masoudi, M.; Kopaei, M.R.; Miraj, S. A comparison of the efficacy of metronidazole vaginal gel and Myrtus (Myrtus communis) extract combination and metronidazole vaginal gel alone in the treatment of recurrent bacterial vaginosis. Avicenna J. Phytomed. 2017, 7, 129–136. [Google Scholar] [PubMed]
  96. Murina, F.; Vicariotto, F.; Di Francesco, S. Thymol, Eugenol and Lactobacilli in a Medical Device for the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis. New Microbiol. 2018, 41, 220–224. [Google Scholar] [PubMed]
  97. Shabanian, S.; Ghahfarrokhi, S.H.; Lotfizadeh, M. Comparative study of the effects of metronidazole gel and Berberis vulgaris gel on the treatment of bacterial vaginosis. J. Appl. Hortic. 2019, 21, 244–248. [Google Scholar] [CrossRef]
  98. Yadav, U.C.S.; Baquer, N.Z. Pharmacological effects of Trigonella foenum-graecum L. in health and disease. Pharm. Biol. 2014, 52, 243–254. [Google Scholar] [CrossRef]
  99. Janda, K.; Gutowska, I.; Geszke-Moritz, M.; Jakubczyk, K. The Common Cichory (Cichorium intybus L.) as a Source of Extracts with Health-Promoting Properties—A Review. Molecules 2021, 26, 1814. [Google Scholar] [CrossRef]
  100. Zagórska, J.; Kukula-Koch, W.; Czop, M.; Iłowiecka, K.; Koch, W. Impact of Thermal Processing on the Composition of Curcuma longa Rhizome. Foods 2023, 12, 3086. [Google Scholar] [CrossRef]
  101. Moga, M.A.; Bălan, A.; Anastasiu, C.V.; Dimienescu, O.G.; Neculoiu, C.D.; Gavriș, C. An Overview on the Anticancer Activity of Azadirachta indica (Neem) in Gynecological Cancers. Int. J. Mol. Sci. 2018, 19, 3898. [Google Scholar] [CrossRef]
  102. Barut, M.; Cavdar, A.S.; Tansı, L.S.; Karaman, Ş. Yield and quality traits of Black Cumin (Nigella sativa L.) genotypes in response to the different sowing dates. Turkish J. Agri. Food Sci. Technol. 2023, 11, 2276–2287. [Google Scholar] [CrossRef]
  103. Wroniak, M.; Krygier, K.; Kaczmarczyk, M. Comparison of the quality of cold pressed and virgin rapeseed oils with industrially obtained oils. Pol. J. Food Nutr. Sci. 2008, 58, 85–89. [Google Scholar]
  104. Tommasi, L.; Negro, C.; Cerfeda, A.; Nutricati, E.; Zuccarello, V.; De Bellis, L.; Miceli, A. Influence of environmental factors on essential oil variability in Thymbra capitata (L.) Cav. growing wild in Southern Puglia (Italy). J. Essent. Oil Res. 2007, 19, 572–580. [Google Scholar] [CrossRef]
  105. Iftikhar, T.; Majeed, H.; Zahra, S.S.; Waheed, M.; Niaz, M.; Bano, N. Thyme. In Essentials of Medicinal and Aromatic Crops; Zia-Ul-Haq, M., AL-Huqail, A.A., Riaz, M., Gohar, U.F., Eds.; Springer Nature: Cham, Switzerland, 2023. [Google Scholar]
  106. Sharafan, M.; Malinowska, M.A.; Ekiert, H.; Kwaśniak, B.; Sikora, E.; Szopa, A. Vitis vinifera (Vine Grape) as a Valuable Cosmetic Raw Material. Pharmaceutics 2023, 15, 1372. [Google Scholar] [CrossRef] [PubMed]
  107. Humphries, T.; Campbell, S.; Florentine, S. Challenges Inherent in Controlling Prickly Pear Species; a Global Review of the Properties of Opuntia stricta, Opuntia ficus-indica and Opuntia monacantha. Plants 2022, 11, 3334. [Google Scholar] [CrossRef] [PubMed]
  108. Mendes, D.S.; Borges, C.E.; de Oliveira, E.A.; Batista, A.C.; da Conceição, C.A.; Duque, T.S.; Araújo, F.H.V.; Moreira, V.H.; do Nascimento, V.G.; de Aguiar Coelho, F.; et al. Assessing current environmental conditions and climate change influences on Syngonanthus nitens (Bong.) Ruhland: An endemic species and economic resource for extractive communities as globally important agricultural heritage systems. Discov. Conserv. 2024, 1, 6. [Google Scholar] [CrossRef]
  109. Costa Drigo, R.T.D.S.; Becker, A.C.; Riesco, M.L.G.; Mascarenhas, V.H.A.; Nick, J.M. Wound-healing properties of Stryphnodendron adstringens (barbatimão) in skin and mucosa injuries: A scoping review protocol. JBI Evid. Synth. 2024, 22, 1610–1616. [Google Scholar] [CrossRef]
  110. Da Trindade, R.; da Silva, J.K.; Setzer, W.N. Copaifera of the neotropics: A review of the phytochemistry and pharmacology. Int. J. Mol. Sci. 2018, 19, 1511. [Google Scholar] [CrossRef]
  111. Fabri, R.L.; Campos, L.M.; Florêncio, J.R.; Oliveira, L.G.; de Oliveira Aragão, D.M.; Ferreira, A.L.P.; de Aguiar, J.A.K.; Apolônio, A.C.M.; Alves, M.S.; Scio, E. Mitracarpus frigidus (Rubiaceae) inhibits inflammatory and oxidative stress mediators in Salmonella sp. mouse infection. J. Pharm. Pharmacol. 2021, 73, 82–92. [Google Scholar] [CrossRef]
  112. Yang, Y.; Sun, X.; Peng, C.; Wei, J.; Yang, X. The Genus Commiphora: An Overview of Its Traditional Uses, Phytochemistry, Pharmacology, and Quality Control. Pharmaceuticals 2024, 17, 1524. [Google Scholar] [CrossRef]
  113. Santos, I.L.; Rodrigues, A.M.d.C.; Amante, E.R.; Silva, L.H.M.d. Soursop (Annona muricata) Properties and Perspectives for Integral Valorization. Foods 2023, 12, 1448. [Google Scholar] [CrossRef]
  114. Aggarwal, B.B.; Sung, B. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol. Sci. 2009, 30, 85–94. [Google Scholar] [CrossRef]
  115. Arzi, L.; Mollaei, H.; Hoshyar, R. Countering Triple Negative Breast Cancer via Impeding Wnt/β-Catenin Signaling, a Phytotherapeutic Approach. Plants 2022, 11, 2191. [Google Scholar] [CrossRef]
  116. Ekiert, H.; Klimek-Szczykutowicz, M.; Szopa, A. Paeonia × suffruticosa (Moutan Peony)—A Review of the Chemical Composition, Traditional and Professional Use in Medicine, Position in Cosmetics Industries, and Biotechnological Studies. Plants 2022, 11, 3379. [Google Scholar] [CrossRef]
  117. Van Der Walt, J.J.A.; Demarne, F. Pelargonium graveolens and P. radens: A comparison of their morphology and essential oils. S. Afr. J. Bot. 1988, 54, 617–622. [Google Scholar] [CrossRef]
  118. Voelker, J.; Shepherd, M.; Mauleon, R. A high-quality draft genome for Melaleuca alternifolia (tea tree): A new platform for evolutionary genomics of myrtaceous terpene-rich species. GigaByte 2021, 2021, gigabyte28. [Google Scholar] [CrossRef] [PubMed]
  119. Dabbaghi, M.M.; Fadaei, M.S.; Soleimani Roudi, H.; Baradaran Rahimi, V.; Askari, V.R. A review of the biological effects of Myrtus communis. Physiol. Rep. 2023, 11, e15770. [Google Scholar] [CrossRef] [PubMed]
  120. Lahlou, R.A.; Samba, N.; Soeiro, P.; Alves, G.; Gonçalves, A.C.; Silva, L.R.; Silvestre, S.; Rodilla, J.; Ismael, M.I. Thymus hirtus Willd. ssp. algeriensis Boiss. and Reut: A Comprehensive Review on Phytochemistry, Bioactivities, and Health-Enhancing Effects. Foods 2022, 11, 3195. [Google Scholar] [CrossRef]
  121. Setiawan, A.; Ito, S.; Mitsuda, Y.; Yamagishi, K.; Hirata, R.; Umar, Y.P. Plant species occurrence and spatial heterogeneity in the understory of a mixed-culture stand for clove (Syzygium aromaticum L.) production in East Java Indonesia. Veg. Sci. 2021, 38, 37–47. [Google Scholar] [CrossRef]
  122. Helander, I.M.; Alakomi, H.L.; Latva-Kala, K.; Mattila-Sandholm, T.; Pol, I.; Smid, E.J.; Gorris, L.G.M.; von Wright, A. Characterization of the action of selected essential oil components on Gram-negative bacteria. J. Agric. Food Chem. 1998, 46, 3590–3595. [Google Scholar] [CrossRef]
  123. Álvarez-Martínez, F.; Barrajón-Catalán, E.; Herranz-López, M.; Micol, V. Antibacterial plant compounds, extracts and essential oils: An updated review on their effects and putative mechanisms of action. Phytomedicine 2021, 90, 153626. [Google Scholar] [CrossRef]
  124. Kazemi, M.; Mousavi, E.; Bandrez, N. Chemical compositions and antibacterial activity of the essential oils of Thymus vulgaris and Tanacetum parthenium. Res. J. Soil. Biol. 2012, 4, 21–31. [Google Scholar] [CrossRef]
  125. Freires, I.d.A.; Murata, R.M.; Furletti, V.F.; Sartoratto, A.; Alencar, S.M.d.; Figueira, G.M.; de Oliveira Rodrigues, J.A.; Duarte, M.C.T.; Rosalen, P.L. Coriandrum sativum L. (Coriander) Essential Oil: Antifungal Activity and Mode of Action on Candida spp., and Molecular Targets Affected in Human Whole-Genome Expression. PLoS ONE 2014, 9, e99086. [Google Scholar] [CrossRef]
  126. Tian, F.; Woo, S.Y.; Lee, S.Y.; Park, S.B.; Zheng, Y.; Chun, H.S. Antifungal Activity of Essential Oil and Plant-Derived Natural Compounds against Aspergillus flavus. Antibiotics 2022, 11, 1727. [Google Scholar] [CrossRef] [PubMed]
  127. Chizzola, R.; Eller, A. Seasonal variability in pyrrolizidine alkaloids in Jacobaea alpina from the Trentino-Alto Adige region (Northern Italy). Chem. Biodivers. 2022, 19, e202200603. [Google Scholar] [CrossRef]
  128. Fuchs, B.; Breuer, T.; Findling, S.; Krischke, M.; Mueller, M.J.; Holzschuh, A.; Krauss, J. Enhanced aphid abundance in spring desynchronizes predator–prey and plant–microorganism interactions. Oecologia 2017, 183, 469–478. [Google Scholar] [CrossRef]
  129. Kaya, D.A.; Arslan, M.; Rusu, L.C. Effects of harvesting hour on essential oil content and composition of Thymus vulgaris. Farmacia 2013, 61, 1194–1203. [Google Scholar]
  130. Krishna, P.D.; Gowrav, M.P.; Bhaskaran, M.; Kruthika, M.R. Current regulations of herbal medicines in the US and EU. Curr. Tradit. Med. 2024, 10, 141–151. [Google Scholar] [CrossRef]
  131. Gerschler, S.; Neumann, N.; Schultze, N.; Guenther, S.; Schulze, C. Quality parameters for the medicinal plant Drosera rotundifolia L.: A new approach with established techniques. Arch. Pharm. 2023, 357, e2300436. [Google Scholar] [CrossRef]
  132. Chelu, M. Hydrogels with Essential Oils: Recent Advances in Designs and Applications. Gels 2024, 10, 636. [Google Scholar] [CrossRef]
  133. Baj, T.; Korona-Głowniak, I.; Kowalski, R.; Malm, A. Chemical Composition and Microbiological Evaluation of Essential Oil from Hyssopus officinalis L. with White and Pink Flowers. Open Chem. 2018, 16, 317–323. [Google Scholar] [CrossRef]
  134. Modearai, M.; Gertsch, J.; Suter, A.; Heinrich, M.; Kortenkamp, A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J. Pharm. Pharmacol. 2007, 59, 567–573. [Google Scholar] [CrossRef]
  135. Roy, A.; Adeline, P.R.; Thangavelu, L. Evaluation of the cytochrome p450 inhibitory effect of thyme oleoresin from Thymus vulgaris L.—An in vitro study. Asian. J. Pharm. Clin. Res. 2018, 11, 149–151. [Google Scholar] [CrossRef]
  136. Vandeweege, S.; Debaene, B.; Lapeere, H.; Verstraelen, H. A systematic review of allergic and irritative contact dermatitis of the vulva: The most important allergens/irritants and the role of patch testing. Contact Dermat. 2023, 88, 249–262. [Google Scholar] [CrossRef] [PubMed]
  137. Paulsen, E. Contact sensitization from Compositae-containing herbal remedies and cosmetics. Contact Dermat. 2002, 47, 189–198. [Google Scholar] [CrossRef] [PubMed]
  138. De Groot, A.C.; Schmidt, E. Tea tree oil: Contact allergy and chemical composition. Contact Dermat. 2016, 75, 129–143. [Google Scholar] [CrossRef]
  139. Gokhale, N.; Mukta, M.S.; Priya, J.; Juhi, B.; Manoj, L.; Prerna, C.; Sumeet, D. Embracing Herbal Wisdom for Vaginal Comfort and Balance: An Insight on Herbal Approach and other therapies in the Treatment of Vaginal Infection Article Sidebar. Afr. J. Biol. Sci. 2024, 6, 625–642. Available online: https://www.afjbs.com/uploads/paper/9bc52a1d9cf1c2f8b2ba8bc145565417.pdf (accessed on 7 January 2025).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.